MINNEAPOLIS, May 26 (UPI) -- MGI Pharma announced Friday U.S. availability of its injectable therapy Dacogen to treat myelodysplastic syndromes.
The company said the Food and Drug Administration approved the drug for market earlier this month.
Dacogen works against both previously treated and untreated forms of MDS, including de novo and secondary MDS of all French-American-British subtypes, MGI said.
Some of those subtypes are refractory anemia; refractory anemia with ringed sideroblasts; refractory anemia with excess blasts; and refractory anemia with excess blasts in transformation.
"In line with our strategy, MGI Pharma continues to expand its presence in oncology and acute care. The introduction of Dacogen is a significant step in our penetration of these markets and in our path to generating $1 billion in total revenue by 2010," said Lonnie Moulder, president and chief executive officer of MGI Pharma.
